Stockpolly
Search
Delisting risk
LSTA · NASDAQ · Biotechnology

Lisata Therapeutics (LSTA)

Develops certepetide for tumor-penetrating cancer therapy combinations.

$1.57
At close0.00 (0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000001000000
Cost of revenue000000000000
Gross profit000001000000
667656654354
Research & development333333322111
333333332243
General & administrative333333332243
Operating income−6−6−7−6−5−5−6−5−4−3−5−4
110000000001
Interest income111000000000
Other non-operating income0−10000000000
Income before tax−5−5−6−5−5−5−6−5−4−3−5−3
Income tax expense00−1000−100000
Net income from continuing operations−5−5−5−5−5−5−5−5−4−3−4−3
Net income−5−5−5−5−5−5−5−5−4−3−4−3
EPS, basic−$0.65−$0.66−$0.65−$0.61−$0.59−$0.55−$0.55−$0.54−$0.49−$0.33−$0.50−$0.32
EPS, diluted−$0.65−$0.66−$0.65−$0.61−$0.59−$0.55−$0.55−$0.54−$0.49−$0.33−$0.50−$0.32
Weighted average shares, basic888888999999
Weighted average shares, diluted888888999999
EBITDA−6−5−6−5−5−5−6−5−4−3−5−4
Depreciation & amortization000000000000
EBIT−6−5−6−5−5−5−6−5−4−3−5−4